Company Description
AgomAb Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need.
Our product candidates are designed to target established pathways and utilize validated modalities with the aim of increasing efficacy while avoiding systemic toxicities in order to overcome the limitations of prior therapeutic approaches.
Our initial focus for the treatment of fibrosis is through inhibition of one of the key signaling pathways involved in fibrosis, the transforming growth factor β, or TGFβ, pathway.
Our mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function to enable patients with these disorders to live fuller and healthier lives.
| Country | Belgium |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 62 |
| CEO | Tim Knotnerus |
Contact Details
Address: Posthoflei 1/6 Antwerpen, 2600 Belgium | |
| Phone | +32 3 318 91 70 |
| Website | agomab.com |
Stock Details
| Ticker Symbol | AGMB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| CIK Code | 2020932 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Tim Knotnerus | Chief Executive Officer and Executive Director |
| Philippe Wiesel | Chief Medical Officer |
| Andrea Sáez | Chief Development Officer |
| Pierre Kemula | Chief Financial Officer |
| Paul van der Horst | Chief Business Officer |
| Ellen Lefever | General Counsel |
| David Epstein | Chairman of the Board of Directors |
| Angelika Jahreis | Non-Executive Director |
| Colin Bond | Non-Executive Director |
| Felice Verduyn—van Weegen | Non-Executive Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 16, 2026 | F-1 | Registration statement for certain foreign private issuers |
| Dec 17, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Oct 28, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jun 20, 2024 | DRS | [Cover] Draft Registration Statement |